Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Sophie S Y Kang und 24 weiteren Autor:innen. Beteiligte Einrichtung: International Vaccine Institute, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Vaccine Development, Clinical Trials, Phase III as Topic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Coalition for Epidemic Preparedness Innovations.
Abstract (Originalsprache)
Background
The swift development of coronavirus disease 2019 (COVID-19) vaccines marked a monumental effort in global coordination and collaboration; however, there remained major disparities in vaccine access and research capacity across countries. Unequal participation in vaccine development studies from low- and middle- income countries (LMICs) clearly signaled an urgent need to strengthen health research infrastructure in those regions.
Methods
With funding from the Gates Foundation (GF), this site readiness initiative carried out rapid capacity enhancement activities to enable large-scale, Phase 3 pivotal clinical trial conduct in LMICs. The International Vaccine Institute (IVI) worked with site partners in four countries (Mozambique, Ghana, Nepal, and the Philippines) after conducting feasibility assessments for site selection. Site-specific gaps were identified, and capacity building activities focused on staff training, site infrastructure, and resource mobilization were carried out over roughly 7 months from October 2020 to May 2021.
Results
Despite pandemic-related challenges such as supply chain shortages, by the end of the capacity building efforts all sites were either contracted to or in discussions with trial sponsors to conduct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine studies. This article provides an overview of the site selection process, critical components of site establishment, and final site readiness evaluations carried out amidst a global health emergency.
Conclusions
This experience illustrates the value of research capacity enhancement as essential to both pandemic preparedness and global health equity. The lessons learned are being carried into an ongoing initiative across West Africa, currently underway as the “Advancing Research Capabilities in West Africa (ARC-WA).”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Vaccine Institute, Seoul, Republic of Korea.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
- Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.
- Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
- Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
ORCID-Profile: Sophie S Y Kang, Birkneh Tilahun Tadesse, Hyon Jin Jeon, Solomon Mequanente Abay, Betelhem I Tekle, Yeonseon Kim, Ilesh V Jani, T Anh Wartel, Florian Marks
Förderung
- Gates Foundation
- Coalition for Epidemic Preparedness Innovations
Zitieren
APA
Kang, S. S. Y., Tadesse, B. T., Jeon, H. J., Fallah, M. P., Dereje, N., Ilesanmi, O. S., Abay, S. M., Tekle, B. I., Son, H. G., Shrestha, L., Shrestha, A., Ramiso, H. V., Canouet, V., Kim, Y., Asante, K. P., Anim, J., Kaali, S., Capeding, M. R., Jani, I. V., …, & Marks, F. (2025). Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf094
Vancouver
Kang SSY, Tadesse BT, Jeon HJ, Fallah MP, Dereje N, Ilesanmi OS, et al. Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf094
BibTeX
@article{Kang2025,
author = {Kang, Sophie S Y and Tadesse, Birkneh Tilahun and Jeon, Hyon Jin and Fallah, Mosoka P and Dereje, Nebiyu and Ilesanmi, Olayinka Stephen and Abay, Solomon Mequanente and Tekle, Betelhem I and Son, Hayoung G and Shrestha, Laxman and Shrestha, Anita and Ramiso, Hasia V and Canouet, Vincent and Kim, Yeonseon and Asante, Kwaku Poku and Anim, Japhet and Kaali, Seyram and Capeding, Maria Rosario and Jani, Ilesh V and Capitine, Igor and Mahumane, Arlete and Wartel, T Anh and Haselbeck, Andrea Haekyung and Saluja, Tarun and Marks, Florian},
title = {Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf094}
}
EUVIMED